Healios K.K. (HLOSF)
OTCMKTS · Delayed Price · Currency is USD
3.435
+0.735 (27.22%)
At close: Jul 14, 2025
Perficient Revenue
Healios K.K. had revenue of 38.00M JPY in the quarter ending March 31, 2025, with 280.00% growth. This brings the company's revenue in the last twelve months to 588.00M, up 374.19% year-over-year. In the year 2024, Healios K.K. had annual revenue of 560.00M with 362.81% growth.
Revenue (ttm)
588.00M JPY
Revenue Growth
+374.19%
P/S Ratio
109.11
Revenue / Employee
9.05M JPY
Employees
65
Market Cap
428.44M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 560.00M | 439.00M | 362.81% |
| Dec 31, 2023 | 121.00M | 31.00M | 34.44% |
| Dec 31, 2022 | 90.00M | 49.00M | 119.51% |
| Dec 31, 2021 | 41.00M | 14.00M | 51.85% |
| Dec 31, 2020 | 27.00M | -252.00M | -90.32% |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |